Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Benjamin L. Schlechter, MD

Medical Oncology

Make an Appointment
Watch Video

No Photo


  • Senior Physician
  • Instructor in Medicine, Harvard Medical School


Contact Information

  • Appointments617-632-5929
  • Office Phone Number857-215-0430


Dr. Schlechter is a medical oncologist who specializes in gastrointestinal cancers including colorectal cancer, anal cancer, pancreatic cancer, and neuroendocrine cancers, among others. He is a former intern, resident, chief resident and fellow at Beth Israel Deaconess Medical Center as well as a member of the faculty at Harvard Medical School. In the past he was the Director of Inpatient Hematology and Oncology at Beth Israel Deaconess Medical Center as well as the Assistant Program Director of the Internal Medicine Residency Program. His work at Dana-Farber focuses on providing excellent patient care while trying to advance the treatment of gastrointestinal cancer patients.

Board Certification:

  • Internal Medicine, 2011
  • Medical Oncology, 2014


  • Beth Israel Deaconess Medical Center


  • Beth Israel Deaconess Medical Center

Medical School:

  • Tel Aviv University


My research interests focus on clinical innovations for patients with gastrointestinal malignancies. I am the Harvard-wide principal investigator for the PANOVA-3 clinical trial studying tumor treating fields in locally advanced pancreatic cancer; NUC-3373, a novel fluorouracil-like drug for colorectal cancer; and the ECOG EA2165 study of nivolumab after chemoradiotherapy for anal squamous cancer. I am on the Data Safety Monitoring Committees of PEN221 for advanced neuroendocrine tumors as well as AbGen107 for advanced gastrointestinal malignancies. I also have enrolled patients in multiple phase I, II, and III clinical trials for gastrointestinal malignancies. I was a lead enroller in the CATIQ phase II trial of isoquercetin to inhibit protein disulfide isomerase to prevent malignancy associated thrombosis in ambulatory cancer patients and have been an active participant in a study of fixed-dose versus weight- based enoxaparin as thromboprophylaxis for hospitalized cancer patients. In the past, I worked as a bench researcher in carcinogenesis in the laboratory of Carol Rosenberg at Boston University Medical Center and at the Wyss Institute for Biologically Inspired Engineering under the direction of Donald Ingber at HMS.


Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Dana-Farber Cancer Institute - Chestnut Hill
300 Boylston Street
Newton, MA 02459
Get Directions